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adherence, some factors associated with better diabetes control
were identiﬁed.
PDB10
ECONOMIC BURDEN OF DIABETIC RETINOPATHY IN
FLORIDA: A PILOT STUDY EXPLORING THE AMOUNT SPENT
USING PRINCIPLE DIAGNOSES
Batiste L, Xiao H
Florida A & M University,Tallahassee, FL, USA
OBJECTIVE: The objective of this study is to determine the
direct medical costs associated with patients who have diabetic
retinopathy and their co-morbidities in the state of Florida.
METHODS: The study was a non-randomized, secondary data
analysis using the Florida Ambulatory Patient Data from 2001.
It was a cross-sectional analysis using the individual patient as
the unit of analysis. The ICD-9 Code 362.02 was used to extract
patients with a principle diagnosis of proliferative diabetic
retinopathy (PDR). The ICD-9 Codes 362.01 and 362.10 were
used to extract patients with a principle diagnosis of nonprolif-
erative diabetic retinopathy (NDR). ICD-9 Code 362.83 was
used to extract patients with macular edema (ME). Patient char-
acteristics along with total charges were extracted for each of
these patients. RESULTS: The total charges for Asian, African
American, and White Hispanic are signiﬁcantly lower than the
total charges for Caucasians. However, Black Hispanics have a
statistically signiﬁcant higher total charge than Caucasians.
Patients with Medicare, Medicare HMO, Medicaid, commercial
HMO, and commercial PPO, have statistically signiﬁcant higher
total charges than patients with commercial insurance. Both
PDR and BDR are associated with statistically signiﬁcant greater
total charges than patients with NDR. Yet, the total charges for
ME are signiﬁcantly lower than those for NDR. This model 
is statistically signiﬁcant. CONCLUSIONS: Total charges are
affected by patient characteristics and severity of diabetic
retinopathy. In the state of Florida for 2001, $3,885,952 were
spent on treating patients with diabetic retinopathy and their 
co-morbidities in the ambulatory setting.
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OBJECTIVE: Type-2 diabetes (T2DM) is associated with
increased morbidity and mortality; however, the onset can be
delayed. This study quantiﬁed the impact of delaying the onset
of frank diabetes on the rate of progression to vascular compli-
cations and all associated costs. METHODS: The Cardiff Dia-
betes Simulation Model was run over a 20-year time horizon
following a cohort of 1000 newly diagnosed T2DM patients
compared to a cohort whose T2DM was delayed by two or ten
years. The model utilised the Framingham equations to predict
cardiovascular events before diabetes and the UKPDS equations
following diagnosis. The transition of predicted risk from 
Framingham to the UKPDS risk level was modelled assuming 
an instantaneous switch (Scenario 1) or a linear-progression
between risk equations (Scenario 2). Direct health care costs
[2004, GBP] and outcomes were each discounted at 3.5%.
RESULTS: Assuming no delay in diabetes, the model predicted
501 myocardial infarctions (MI’s), 252 strokes and 2505
microvascular events. Mean costs and quality adjusted life years
(QALY’s) per subject were £11,972 and 7.3 years, respectively.
Mean costs savings ranged from -£2376 to -£4791 (Scenario 1)
and -£123 to -£573 (Scenario 2) through delaying diabetes by
two and ten years, respectively. Mean change in QALY’s ranged
from 0.6 to 1.7 years (Scenario 1) and 0.1 to 1.2 (Scenario 2),
respectively. The number of MI’s avoided ranged from 40 to 224;
while the predicted number of strokes avoided ranged from 37
to 147 for a two-year and ten-year delay, respectively. CON-
CLUSIONS: This study demonstrated that even modest delays
in the onset of diabetes can have a substantial impact on pre-
dicted vascular events and ﬁnancial costs. However, the magni-
tude of this impact was highly dependent upon the modelling
assumption employed relating to the change in cardiovascular
risk as people progress to frank T2DM.
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OBJECTIVE: Glycosylated hemoglobin (HbA1c) is a well-
established measure of glycemic control. Understanding the
impact of staying at target HbA1c levels (£7.0%) on treatment
costs would be of great signiﬁcance to managed care organiza-
tions. The goal of this study was to determine whether being at
target HbA1c results in reductions in diabetes-related costs.
METHODS: This study was a retrospective database analysis
using eligibility, medical and pharmacy claims data, and labora-
tory data from a large US health care organization. Subjects were
included in the study if they had two or more claims for type-2
diabetes and at least one HbA1c value during the period January
1, 2002 through December 31, 2002 (ﬁrst such date identiﬁed
as index date). Subjects with two or more claims for type-1 dia-
betes were excluded from the study. Study subjects were divided
into those at target HbA1c (£7.0%) and above target HbA1c
(>7.0%) and were followed for a period of one year following
their index date. Demographic, clinical and cost variables were
extracted for each subject. Multiple linear regression analysis
was used to compare treatment costs between subjects at target
level and subjects above target level. RESULTS: A total of 3121
subjects were identiﬁed as being continuously at target level and
3659 subjects were identiﬁed as being continuously above target
level. The target group was associated with 30% lower total 
diabetes costs (p < 0.01) after controlling for the confounding
factors (age, gender, health plan region and presence of co-
morbid conditions). The predicted total diabetes costs in the
target group was $1171 and the predicted costs in the above
target group was $1540. CONCLUSION: Results of this analy-
sis suggests that staying at target HbA1c level was associated with
cost savings over a one-year follow-up period in a managed care
setting.
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OBJECTIVES: To collect cost data on the complications of 
diabetes from published sources in France, Germany, Spain and
Italy for use in a peer-reviewed, validated diabetes model.
METHODS: A search for published cost of diabetes complica-
tions data was performed in peer-reviewed journals listed in
PubMed and ISPOR conference proceedings from the last ten
years. Where country-speciﬁc data were not available, we
referred to government websites and local cost experts. Identi-
ﬁed costs were inﬂated to 2004 Euros (€). Major complication
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costs are presented. RESULTS: First year costs of non-fatal
myocardial infarction varied between 15,592€ in France and
4,089€ in Spain. In subsequent years of treatment, this range was
1226€ (France) to 738€ (Spain). Angina costs were similar across
all four countries: 2613€ in France; 3342€ in Germany; 2297€
in Italy; and 2207€ in Spain. Event costs of non-fatal stroke were
higher in Germany (19,399€) than in other countries (France
11,754€; Italy 6,583€; Spain 4,638€). Event costs of end-stage
renal disease varied depending on the type of dialysis in 
France (24,608–56,487€), Germany (46,296–68,175€), Italy
(43,075–56,717€) and Spain (28,370–32,706€). Lower extrem-
ity amputation costs were 31,998€ (France); 22,096€ (Germany);
10,177€ (Italy); and 14,787€ (Spain). CONCLUSIONS: Overall,
our search showed costs are well documented in France and
Germany, but revealed a paucity of data for Spain and Italy.
Spanish costs, collected by contacting local experts and from
government reports, generally appeared to be lower for treating
cardiovascular complications than in other countries. Italian
costs reported in the literature were primarily hospitalization
costs derived from diagnosis-related groups, and therefore likely
to overestimate the cost of speciﬁc complications. Additional
research is required to document complication costs in Spain and
Italy. These data are essential for creating models of diabetes able
to accurately simulate the cumulative costs associated with the
progression of this disease and its complications.
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OBJECTIVES: In a recent randomized, controlled clinical study
in patients with type-1 diabetes, use of insulin detemir (IDet)
versus neutral protamine Hagedorn (NPH) insulin in a basal
(twice daily)/bolus regimen with insulin aspart (IAsp) as bolus,
demonstrated that IDet/IAsp was associated with a relative risk
reduction of 21% for hypoglycaemic events (p < 0.05), a reduc-
tion of 1.01kg in body weight (p < 0.05) and decreased systolic
blood pressure (SBP) (3mmHg, p < 0.05) versus NPH/IAsp over
six months of treatment. No signiﬁcant difference in HbA1c was
noted. The aim of this analysis was to assess the impact of these
changes over long-term treatment with IDet/IAsp versus
NPH/IAsp. METHODS: The CORE Diabetes Model, a peer-
reviewed, validated computer simulation model, was used to
project these short-term ﬁndings to evaluate long-term clinical
and cost outcomes. Transition probabilities and risk adjustments
were derived from published studies. Baseline cohort character-
istics were taken from the clinical trial. Total direct costs 
(complications + treatment costs) were derived from published
sources and projected over patients’ lifetimes from a Dutch
National Health care perspective. Costs and clinical beneﬁts
were discounted at 3.5% per annum. RESULTS: Decreased inci-
dence of hypoglycemic events, improved BMI and SBP associ-
ated with IDet/IAsp treatment led to fewer diabetes-related
complications, increased life expectancy (0.17 years) and
improved quality-adjusted life expectancy (0.11 QALYs) com-
pared to NPH/IAsp. Mean total lifetime costs were 626€/patient
higher in the IDet/IAsp treatment arm than in the NPH/IAsp
group, leading to incremental cost-effectiveness ratios of 3682€
per LYG and 5691€ per QALY gained. CONCLUSIONS: Short-
term clinical improvements associated with IDet/IAsp were pro-
jected to lead to a lower incidence of complications, improved
life expectancy and quality-adjusted life expectancy over patient
lifetimes. Reductions in the cost of complication partially offset
the costs of IDet/IAsp treatment, leading to incremental cost-
effectiveness ratios within the range considered to represent
excellent value for money.
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OBJECTIVES: To assess the cost-effectiveness of various screen-
ing intervals using indirect ophthalmoscopy performed by oph-
thalmologists for detecting diabetic retinopathy among type-2
diabetic patients from hospital and societal perspectives in 
Thailand. METHODS: A Markov model of diabetes retinopa-
thy was constructed based on Eastman model. A cohort of
10,000 newly diagnosed, type-2 diabetic patients age 40 years
was simulated until the age of 75 years or death. Transition prob-
abilities were obtained from literature review, while unit costs
and utilization patterns in Thai population were derived from a
hospital and expert opinions. Costs of screening and treatment
were calculated using a microcosting technique. Incremental
cost-effectiveness analyses were performed based on a cohort
simulation and presented as incremental Baht per blindness 
prevented. A series of sensitivity analyses were performed.
RESULTS: In base-case analysis using a hospital perspective, an
incremental cost-effectiveness ratio (ICER) of screening every
four-years compared to no screening was 85,976 Baht per blind-
ness prevented. Comparing to the next preceding screening fre-
quency, the ICER of screening frequency every four-years, every
three-years, and two-years was 62,806, 70,554, 95,865 Baht 
per blindness prevented, respectively. When varying the cost of
screening and laser treatment, probability of seeking medical
treatment among unscreened, probability of being treated with
vitrectomy, and annual mortality rate, the results remained
similar to the base-case analysis. However, when we performed
analysis using a societal perspective, all screening patterns
resulted in cost-saving. CONCLUSIONS: Our ﬁndings indicated
that an incremental cost incurred from increasing frequency in
all screening intervals was less than 100,000 Baht or US$2,500
per one blindness prevented. Annual diabetic retinopathy screen-
ing seems to be a cost-effectiveness intervention, especially from
a societal perspective. Our ﬁndings can be a very useful infor-
mation to aid health care policy decision makers during their
decision making process.
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OBJECTIVE: To examine how the type-2 diabetes-related direct
medical costs are associated with an individual’s level of glycemic
control. METHODS: The analysis was performed on data from
a large health plan administrative database. Individuals were
deﬁned an index date between October 1, 1999 and April 30,
2001, based upon ﬁrst diagnosis of diabetes or use of antidia-
betic agent and were retrospectively examined in the 12 months
pre- and 24–43 months post-index date (N = 10,780). Differ-
